Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ding Li, Ding Wang, Haofeng Liu & Xiaohui Jiang. (2022) LEM domain containing 1 (LEMD1) transcriptionally activated by SRY-related high-mobility-group box 4 (SOX4) accelerates the progression of colon cancer by upregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway. Bioengineered 13:4, pages 8087-8100.
Read now
Read now
Zeev Elkoshi. (2021) The Binary Classification of Protein Kinases. Journal of Inflammation Research 14, pages 929-947.
Read now
Read now
Jinrong Qiu, Fuping Zhou, Xinchun Li, Sufang Zhang, Zhuo Chen, Zenghui Xu, Gaoxiong Lu, Zhi Zhu, Na Ding, Jinxing Lou, Zhenlong Ye & Qijun Qian. (2020) Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients. Cancer Management and Research 12, pages 209-219.
Read now
Read now
Maria Vassilakopoulou, Kazuto Harada & Jaffer A Ajani. (2018) Ramucirumab for the treatment of gastric adenocarcinoma. Expert Opinion on Orphan Drugs 6:8, pages 449-455.
Read now
Read now
Haifeng Qiu, Jing Li, Qiuli Liu, Mei Tang & Yuan Wang. (2018) Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle 17:10, pages 1235-1244.
Read now
Read now
Articles from other publishers (22)
Atsushi Nakamura, Ou Yamaguchi, Keita Mori, Keita Miura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi & Kyoichi Kaira. (2023) Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer 184, pages 62-72.
Crossref
Crossref
Hamidreza Zalpoor, Fatemeh Aziziyan, Mahsa Liaghat, Maryam Bakhtiyari, Abdullatif Akbari, Mohsen Nabi-Afjadi, Razieh Forghaniesfidvajani & Nima Rezaei. (2022) The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Communication and Signaling 20:1.
Crossref
Crossref
Kyoichi Kaira, Hisao Imai, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Atsuto Mouri, Kunihiko Kobayashi, Masanori Yasuda & Hiroshi Kagamu. (2022) Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC. Oncology Reports 48:6.
Crossref
Crossref
Yiran Qiu, Shouyu Ke, Jieqiong Chen, Zhizhen Qin, Wenle Zhang, Yaqin Yuan, Dehua Meng, Gang Zhao, Kejin Wu, Bin Li & Dan Li. (2022) FOXP3+ regulatory T cells and the immune escape in solid tumours. Frontiers in Immunology 13.
Crossref
Crossref
Kenji Nakahama, Hiroyasu Kaneda, Masahiko Osawa, Mitsuru Fukui, Motohiro Izumi, Naoki Yoshimoto, Akira Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Yoshiya Matsumoto, Kenji Sawa, Yoko Tani, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai & Tomoya Kawaguchi. (2022) Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non–small cell lung cancer. Cancer Science 113:9, pages 3148-3160.
Crossref
Crossref
Yun Liu, Yang Li, Yuxi Wang, Congcong Lin, Dan Zhang, Juncheng Chen, Liang Ouyang, Fengbo Wu, Jifa Zhang & Lei Chen. (2022) Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Puneet Raman, Gehan Botrus & Tanios Bekaii-Saab. 2022.
Davinder Singh, Divya Dheer, Abhilash Samykutty & Ravi Shankar. (2021) Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. Journal of Controlled Release 340, pages 1-34.
Crossref
Crossref
Xiao Fu, Yingni He, Mu Li, Zezhi Huang & Masoud Najafi. (2021) Targeting of the tumor microenvironment by curcumin. BioFactors 47:6, pages 914-932.
Crossref
Crossref
Raquel Muñoz, Alessandra Girotti, Denise Hileeto & Francisco Javier Arias. (2021) Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. Cancers 13:21, pages 5414.
Crossref
Crossref
Zhigang Zhang, Chenghui Yang, Lili Li, Ying Zhu, Ke Su, Lingyun Zhai, Zhen Wang & Jian Huang. (2021) “γδT Cell-IL17A-Neutrophil” Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Shu‐Jin Li, Jia‐Xian Chen & Zhi‐Jun Sun. (2021) Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Communications 41:9, pages 830-850.
Crossref
Crossref
Alexander Batista-Duharte, Alejandra Pera, Salvador F. Aliño & Rafael Solana. (2021) Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. International Immunopharmacology 96, pages 107761.
Crossref
Crossref
Colleen S. Curran & Jeffrey B. Kopp. (2021) PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrology 22:1.
Crossref
Crossref
Zala Lužnik, Sonia Anchouche, Reza Dana & Jia Yin. (2020) Regulatory T Cells in Angiogenesis. The Journal of Immunology 205:10, pages 2557-2565.
Crossref
Crossref
Stephen P. Hack, Andrew X. Zhu & Yulei Wang. (2020) Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology 11.
Crossref
Crossref
Sami Znati, Rebecca Carter, Marcos Vasquez, Adam Westhorpe, Hassan Shahbakhti, Jessica Prince, Petra Vlckova, Chiara De Vellis, Zainab Bascal, Marilena Loizidou & Ricky A. Sharma. (2020) Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib. Cancers 12:7, pages 1878.
Crossref
Crossref
Sadal Refae, Jocelyn Gal, Patrick Brest, Damien Giacchero, Delphine Borchiellini, Nathalie Ebran, Frederic Peyrade, Joël Guigay, Gérard Milano & Esma Saada-Bouzid. (2020) Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Scientific Reports 10:1.
Crossref
Crossref
Jung-Ho Kim, Beom Seok Kim & Sang-Kyou Lee. (2020) Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Network 20:1.
Crossref
Crossref
Oisun Jung, DeannaLee M. Beauvais, Kristin M. Adams & Alan C. Rapraeger. (2019) VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. Journal of Cell Science.
Crossref
Crossref
Cheng Zhang, Ning Wang, Hor-Yue Tan, Wei Guo, Sha Li & Yibin Feng. (2018) Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine. Integrative Cancer Therapies 17:3, pages 582-601.
Crossref
Crossref
Sadaf Hameed, Pravin Bhattarai & Zhifei Dai. (2018) Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Science China Life Sciences 61:4, pages 380-391.
Crossref
Crossref